We will attend CIMT Annual Meeting 2024, taking place between May 15-17 in Mainz, Germany. A poster presentation (No. 127, Session II) and a talk session (Short Talk Session VI) will be held by one of our clinicians about "Pattern of tumor regression of recurrent glioblastoma after intratumoral virus injection of oncolytic parvovirus H-1 strongly supports virus contribution in effective viro-immunotherapy". We are looking forward to meeting you!

We have launched a new website: Besides technical upgrades and design changes reflecting ORYX' innovative and dynamic approach to fight cancer, clinical data have been updated. Feel free to give us feedback!

The article "Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application" by German Cancer Research Center's Tumor Virology Team has been published online in peer-reviewed Applied Microbiology and Biotechnology. It focusses on the stability and environmental safety of ParvOryx from manufacturing up to its use in patients, including hold-stops in manufacturing, stability, stress testing and de- and rehydration for lyophilization simulation.

Article